Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Defactinib + RO5126766 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Defactinib | VS-6063|PF-04554878 | FAK inhibitor 15 | Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (PMID: 31739184). | |
RO5126766 | Avutometinib|VS-6766|VS6766|VS 6766|CH5126766|CH-5126766|R-7304|RG-7304 | MEK inhibitor (Pan) 23 MEK1 Inhibitor 25 MEK2 Inhibitor 23 RAF Inhibitor (Pan) 27 | RO5126766 (VS-6766) is a RAF/MEK inhibitor, which potentially leads to decreased tumor cell growth and inhibition of tumor growth (PMID: 34288272). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05787561 | Phase II | Defactinib + RO5126766 | A Study of VS-6766 and Defactinib in People With Mesonephric Gynecologic Cancer | Recruiting | USA | 0 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT04620330 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202) | Recruiting | USA | ITA | FRA | ESP | DEU | 0 |
NCT04720417 | Phase II | Defactinib + RO5126766 | Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
NCT05512208 | Phase II | Defactinib + RO5126766 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | Recruiting | USA | 0 |